Capital International Inc. CA Invests $1.15 Million in Ascendis Pharma A/S (NASDAQ:ASND)

Capital International Inc. CA purchased a new position in Ascendis Pharma A/S (NASDAQ:ASND) during the fourth quarter, HoldingsChannel reports. The institutional investor purchased 8,375 shares of the biotechnology company’s stock, valued at approximately $1,153,000.

A number of other large investors also recently bought and sold shares of ASND. Wilmington Savings Fund Society FSB purchased a new position in shares of Ascendis Pharma A/S in the 3rd quarter worth $30,000. Jones Financial Companies Lllp grew its holdings in shares of Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 197 shares during the period. Blue Trust Inc. increased its position in Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 328 shares in the last quarter. GAMMA Investing LLC raised its holdings in Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 214 shares during the period. Finally, Sanctuary Advisors LLC acquired a new position in Ascendis Pharma A/S during the fourth quarter valued at approximately $203,000.

Analyst Ratings Changes

A number of equities analysts have recently commented on ASND shares. Evercore ISI raised their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an “outperform” rating in a research note on Tuesday, February 18th. The Goldman Sachs Group boosted their price objective on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Morgan Stanley set a $180.00 target price on Ascendis Pharma A/S in a research note on Tuesday, February 18th. Cantor Fitzgerald boosted their price target on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 25th. Finally, Royal Bank of Canada began coverage on shares of Ascendis Pharma A/S in a research note on Wednesday, April 16th. They set an “outperform” rating and a $205.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $204.67.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock opened at $165.05 on Monday. The firm has a market cap of $10.06 billion, a PE ratio of -23.25 and a beta of 0.54. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $169.37. The firm’s 50-day simple moving average is $152.00 and its 200-day simple moving average is $138.12.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.64. On average, equities analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.